The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 4
  • 1
    Veraart, Manon Cecile Elisabeth
    Director born in August 1987
    Individual (7 offsprings)
    Officer
    2022-06-06 ~ now
    OF - director → CIF 0
  • 2
    Pfeiffer, Thomas
    Director born in October 1987
    Individual (2 offsprings)
    Officer
    2022-06-06 ~ now
    OF - director → CIF 0
  • 3
    Wilde, Lars Christian
    Director born in August 1985
    Individual (5 offsprings)
    Officer
    2022-06-06 ~ now
    OF - director → CIF 0
  • 4
    1st Floor, One Suffolk Way, Sevenoaks, Kent, England
    Corporate (6 parents, 4 offsprings)
    Equity (Company account)
    Retained earnings (accumulated losses)
    -3,615,628 GBP2023-12-31
    Person with significant control
    2022-06-06 ~ now
    PE - Ownership of shares – 75% or moreCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
    PE - Right to appoint or remove directorsCIF 0
Ceased 1
  • Kranzler, Jay Daniel
    Director born in February 1958
    Individual
    Officer
    2022-10-17 ~ 2023-07-18
    OF - director → CIF 0
parent relation
Company in focus

KORE THERAPEUTICS LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Debtors
37,901 GBP2023-12-31
35,933 GBP2022-12-31
Cash at bank and in hand
0 GBP2023-12-31
60,643 GBP2022-12-31
Current Assets
37,901 GBP2023-12-31
96,576 GBP2022-12-31
Creditors
Current, Amounts falling due within one year
-236,238 GBP2023-12-31
-168,846 GBP2022-12-31
Net Current Assets/Liabilities
-198,337 GBP2023-12-31
-72,270 GBP2022-12-31
Equity
Called up share capital
10 GBP2023-12-31
10 GBP2022-12-31
Retained earnings (accumulated losses)
-198,347 GBP2023-12-31
-72,280 GBP2022-12-31
Equity
-198,337 GBP2023-12-31
-72,270 GBP2022-12-31
Average Number of Employees
32023-01-01 ~ 2023-12-31
32022-06-06 ~ 2022-12-31
Amount of corporation tax that is recoverable
Current
37,879 GBP2023-12-31
25,963 GBP2022-12-31
Other Debtors
Amounts falling due within one year
22 GBP2023-12-31
9,970 GBP2022-12-31
Debtors
Current, Amounts falling due within one year
37,901 GBP2023-12-31
35,933 GBP2022-12-31
Trade Creditors/Trade Payables
Current
7,500 GBP2023-12-31
44,252 GBP2022-12-31
Other Creditors
Current
228,738 GBP2023-12-31
124,594 GBP2022-12-31
Creditors
Current
236,238 GBP2023-12-31
168,846 GBP2022-12-31

  • KORE THERAPEUTICS LTD
    Info
    Registered number 14150623
    1st Floor One Suffolk Way, Sevenoaks, Kent TN13 1YL
    Private Limited Company incorporated on 2022-06-06 (3 years). The company status is Active.
    The last date of confirmation statement was made at 2024-06-05
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.